phrykt

Onconetix, Inc. (ONCO): who owns it and who trades it

As of Nov 9, 2026, ONCO insiders reported 3 open-market sales worth $144K and 3 purchases worth $153K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Hrt Financial Lp (10% owner), with $144K.

Latest filing Nov 9, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, ONCO insiders reported $153K of open-market purchases and $144K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$153K
3 trades, 1 people
Sales, 12 months
$144K
3 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Apr 21, 2026
Filed Apr 22, 2026

Purchases and sales by month

$153K$153KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 21, 2026Hrt Financial Lp10% ownerSale49,710$0.69$34.3KForm 4
Apr 20, 2026Hrt Financial Lp10% ownerSale94,462$0.75$70.8KForm 4
Apr 17, 2026Hrt Financial Lp10% ownerPurchase34,636$0.73$25.3KForm 4
Apr 16, 2026Hrt Financial Lp10% ownerSale53,867$0.73$39.3KForm 4
Apr 15, 2026Hrt Financial Lp10% ownerPurchase92,554$0.76$70.3KForm 4
Apr 14, 2026Hrt Financial Lp10% ownerPurchase74,350$0.77$57.2KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Hrt Financial Lp10% owner$153K$144KApr 21, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ONCO short interest

Very high short interest. 24.2% of ONCO shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 1599%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 957,609 ONCO shares were sold short, 24.2% of the shares outstanding, up 145.6% from the report before. At the average daily volume of 5.37M shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

24.2%May 15Oct 3027.8%

Days to cover

1.0May 15Oct 301.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026957,60924.25%+146%5.37M1.0
Oct 15, 2026389,8719.87%-20%4.75M1.0
Sep 30, 2026489,62112.40%+262%10.33M1.0
Sep 15, 2026135,3203.43%-20%1.01M1.0
Aug 31, 2026168,2344.26%+11%225,6221.0
Aug 14, 2026152,1013.85%-22%182,2311.0
Jul 31, 2026196,1725.47%+60%360,9961.0
Jul 15, 2026122,2443.41%+98%1.03M1.0
Jun 30, 202661,6151.72%+231%1.08M1.0
Jun 15, 202618,6300.52%-64%372,1241.0
May 29, 202651,8831.45%-8%2.95M1.0
May 15, 202656,3691.57%-89%909,3361.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Onconetix company events

Onconetix filed 17 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026RulesChanged its bylaws or articles. Filing
  2. Nov 6, 2026AgreementFirst Amendment to Share Exchange Agreement As previously disclosed, on February 11, 2026, Onconetix, Inc., a Delaware corporation, entered into a Share Exchange Agreement, by and among (i) Onconetix, (ii) Realbotix Corp., a company existing under the laws of the Province of Ontario, (iii)… Filing
  3. Oct 26, 2026AnnouncementAs previously reported on a Current Report on Form 8-K filed on May 4, 2026, Onconetix, Inc. held a special meeting of stockholders on April 30, 2026. Filing
  4. Oct 23, 2026AnnouncementOnconetix, Inc. made an additional advance of $500,000 to Realbotix, LLC pursuant to that certain Grid Promissory Note, dated September 11, 2026, previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 14, 2026. Filing
  5. Sep 14, 2026AgreementOnconetix, Inc. entered into a Grid Promissory Note with Realbotix, LLC, pursuant to which the Company agreed to make available to Realbotix loans in an of up to $5.0 million, of which $2.5 million was advanced on September 11, 2026. Filing
  6. Jul 29, 2026AgreementOnconetix, Inc., a Delaware corporation, entered into a securities purchase agreement with an accredited investor, pursuant to which the Company agreed to issue and sell to the PIPE Investor an aggregate of 37,812 shares of Series F convertible preferred stock, par value $0.00001 per share, for an… Filing
  7. May 19, 2026AnnouncementThe Company issued a press release announcing the Reverse Stock Split, a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. Filing
  8. May 14, 2026AnnouncementOnconetix, Inc. issued a press release on the first quarter operational and clinical progress of its fully-owned Swiss subsidiary, Proteomedix AG, a developer of Proclarix®, a diagnostic blood test used in combination with prostate-specific antigen to identify clinically significant prostate cancer. Filing
  9. May 4, 2026VoteReported shareholder vote results. Filing
  10. Apr 24, 2026LeadershipResignation of Andrew Oakley and Thomas Meier as Directors; Elections of Sammy Dorf as Chairman of the Board Effective on April 20, 2026, Andrew Oakley and Thomas Meier notified the Board of Directors of Onconetix, Inc, a Delaware corporation, of their resignation from the Board. Filing
  11. Mar 27, 2026AnnouncementThe Company issued a press release announcing the Reverse Stock Split, a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. Filing
  12. Mar 25, 2026LeadershipAmended an earlier report. The Board of Directors of Onconetix, Inc, a Delaware corporation appointed David White as Chief Executive Officer of the Company effective as of that date. Filing
  13. Mar 24, 2026LeadershipThe Board of Directors of Onconetix, Inc, a Delaware corporation appointed David White as Chief Executive Officer of the Company effective as of that date. Filing
  14. Feb 12, 2026AgreementThis section describes the material provisions of the Share Exchange Agreement (as defined below) but does not purport to describe all of the terms thereof. Filing
  15. Feb 9, 2026VoteReported shareholder vote results. Filing
  16. Dec 10, 2025LeadershipThe Compensation Committee of the Board of Directors of Onconetix, Inc. held a meeting to review and approve certain executive compensation matters. Filing
  17. Dec 10, 2025AgreementProteomedix AG, a Swiss Company, a wholly-owned subsiairy of Onconetix, Inc., entered into an amendment of the license agreement with Laboratory Corporation of America Holdings dated as of March 27, 2023, by and between the Company and Labcorp, pursuant to which Labcorp has the exclusive right to… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Onconetix financials

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ONCO in the last 120 days.

FiledHolderFormStake
Nov 5, 2026Keystone Capital Partners, LLC13G/A6.3%
Nov 5, 2026Keystone Capital Partners, LLC13G/A6.3%

Questions about Onconetix, Inc. (ONCO) stock

Are ONCO insiders buying or selling?

In the last 12 months, ONCO insiders reported 3 open-market purchases worth $153K and 3 sales worth $144K. The latest trade was on Apr 21, 2026. See every trade.

What is the short interest in ONCO?

As of Oct 30, 2026, 957,609 ONCO shares were sold short, 24.2% of the shares outstanding, up 145.6% from the report before. At the average daily volume of 5.37M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.